Loading...

We've got a brand new version of Simply Wall St! Try it out

Newron Pharmaceuticals

SWX:NWRN
Snowflake Description

Flawless balance sheet with exceptional growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NWRN
SWX
CHF105M
Market Cap
  1. Home
  2. CH
  3. Pharmaceuticals & Biotech
Company description

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The last earnings update was 164 days ago. More info.


Add to Portfolio Compare Print
  • Newron Pharmaceuticals has significant price volatility in the past 3 months.
NWRN Share Price and Events
7 Day Returns
-3%
SWX:NWRN
-1.5%
CH Pharmaceuticals
-1.7%
CH Market
1 Year Returns
-46.4%
SWX:NWRN
8.3%
CH Pharmaceuticals
1.5%
CH Market
NWRN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Newron Pharmaceuticals (NWRN) -3% -6.3% -27.2% -46.4% -70.9% -63.6%
CH Pharmaceuticals -1.5% -0.2% 2% 8.3% 10.3% 4.2%
CH Market -1.7% -2.3% -0.6% 1.5% 14% 10.7%
1 Year Return vs Industry and Market
  • NWRN underperformed the Pharmaceuticals industry which returned 8.3% over the past year.
  • NWRN underperformed the Market in Switzerland which returned 1.5% over the past year.
Price Volatility
NWRN
Industry
5yr Volatility vs Market

NWRN Value

 Is Newron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Newron Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Newron Pharmaceuticals.

SWX:NWRN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.5%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:NWRN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 9%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.701 (1 + (1- 24%) (0%))
0.8
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.8 * 9.02%)
10.49%

Discounted Cash Flow Calculation for SWX:NWRN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Newron Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:NWRN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 10.49%)
2020 -45.00 Analyst x1 -40.73
2021 121.00 Analyst x1 99.11
2022 201.00 Analyst x1 149.01
2023 311.00 Analyst x1 208.67
2024 407.66 Est @ 31.08% 247.55
2025 500.36 Est @ 22.74% 274.99
2026 584.92 Est @ 16.9% 290.94
2027 659.86 Est @ 12.81% 297.05
2028 725.52 Est @ 9.95% 295.60
2029 783.19 Est @ 7.95% 288.80
Present value of next 10 years cash flows €2,111.00
SWX:NWRN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €783.19 × (1 + 3.28%) ÷ (10.49% – 3.28%)
€11,208.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €11,208.96 ÷ (1 + 10.49%)10
€4,133.29
SWX:NWRN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,111.00 + €4,133.29
€6,244.30
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €6,244.30 / 17.85
€349.91
SWX:NWRN Discount to Share Price
Calculation Result
Exchange Rate EUR/CHF
(Reporting currency to currency of SWX:NWRN)
1.087
Value per Share
(CHF)
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €349.91 x 1.087
CHF380.49
Value per share (CHF) From above. CHF380.49
Current discount Discount to share price of CHF5.90
= -1 x (CHF5.90 - CHF380.49) / CHF380.49
98.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Newron Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is CHF5.9 vs Future cash flow value of CHF380.49
Current Discount Checks
For Newron Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Newron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Newron Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Newron Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Newron Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:NWRN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.84
SWX:NWRN Share Price ** SWX (2019-08-16) in CHF CHF5.9
SWX:NWRN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.92 €5.43
Europe Pharmaceuticals Industry PE Ratio Median Figure of 46 Publicly-Listed Pharmaceuticals Companies 25.9x
Switzerland Market PE Ratio Median Figure of 172 Publicly-Listed Companies 17.58x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Newron Pharmaceuticals.

SWX:NWRN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:NWRN Share Price ÷ EPS (both in EUR)

= 5.43 ÷ -0.84

-6.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Newron Pharmaceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Newron Pharmaceuticals is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does Newron Pharmaceuticals's expected growth come at a high price?
Raw Data
SWX:NWRN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
63.4%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 37 Publicly-Listed Pharmaceuticals Companies 1.84x
Switzerland Market PEG Ratio Median Figure of 122 Publicly-Listed Companies 2.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Newron Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Newron Pharmaceuticals's assets?
Raw Data
SWX:NWRN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €3.07
SWX:NWRN Share Price * SWX (2019-08-16) in CHF CHF5.9
SWX:NWRN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.92 €5.43
Switzerland Pharmaceuticals Industry PB Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 3.35x
Switzerland Market PB Ratio Median Figure of 215 Publicly-Listed Companies 1.55x
SWX:NWRN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:NWRN Share Price ÷ Book Value per Share (both in EUR)

= 5.43 ÷ 3.07

1.77x

* Primary Listing of Newron Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Newron Pharmaceuticals is good value based on assets compared to the CH Pharmaceuticals industry average.
X
Value checks
We assess Newron Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Newron Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NWRN Future Performance

 How is Newron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Newron Pharmaceuticals expected to grow at an attractive rate?
  • Newron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Newron Pharmaceuticals's earnings growth is expected to exceed the Switzerland market average.
  • Newron Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:NWRN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:NWRN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 63.4%
SWX:NWRN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 61.9%
Switzerland Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 8.1%
Switzerland Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.1%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.8%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:NWRN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:NWRN Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 400 249 221 2
2022-12-31 291 176 158 2
2021-12-31 89 93 94 2
2020-12-31 18 -38 -39 4
2019-12-31 10 -29 -29 4
SWX:NWRN Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -16 -15
2018-09-30 4 -16 -15
2018-06-30 4 -16 -14
2018-03-31 9 -12 -10
2017-12-31 13 -8 -5
2017-09-30 14 -10 -5
2017-06-30 15 -12 -5
2017-03-31 11 -16 -10
2016-12-31 7 -20 -15
2016-09-30 6 -18 -20
2016-06-30 4 -17 -25
2016-03-31 3 -15 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Newron Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Newron Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:NWRN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Newron Pharmaceuticals Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:NWRN Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 10.01 10.01 10.01 1.00
2022-12-31 8.57 8.57 8.57 1.00
2021-12-31 1.64 4.03 -0.75 2.00
2020-12-31 -1.76 -0.92 -2.46 3.00
2019-12-31 -1.02 -0.80 -1.43 3.00
SWX:NWRN Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.84
2018-09-30 -0.84
2018-06-30 -0.83
2018-03-31 -0.59
2017-12-31 -0.32
2017-09-30 -0.32
2017-06-30 -0.31
2017-03-31 -0.66
2016-12-31 -1.04
2016-09-30 -1.40
2016-06-30 -1.78
2016-03-31 -1.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Newron Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Newron Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Newron Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NWRN Past Performance

  How has Newron Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Newron Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Newron Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Newron Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Newron Pharmaceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Newron Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Newron Pharmaceuticals Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:NWRN Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.03 -15.04 9.19 9.82
2018-09-30 3.89 -14.73 9.17 9.22
2018-06-30 3.75 -14.42 9.16 8.62
2018-03-31 8.59 -9.85 9.33 8.32
2017-12-31 13.43 -5.28 9.50 8.03
2017-09-30 13.97 -5.10 9.87 8.20
2017-06-30 14.51 -4.93 10.25 8.37
2017-03-31 10.62 -10.08 10.13 10.20
2016-12-31 6.73 -15.24 10.01 12.04
2016-09-30 5.52 -19.94 9.56 13.48
2016-06-30 4.31 -24.65 9.10 14.92
2016-03-31 3.34 -23.73 8.84 13.20
2015-12-31 2.38 -22.82 8.58 11.48
2015-09-30 2.26 -17.62 8.04 8.64
2015-06-30 2.14 -12.42 7.50 5.80
2015-03-31 1.85 -11.26 7.23 4.75
2014-12-31 1.56 -10.10 6.95 3.70
2014-09-30 2.17 -9.67 6.88 3.86
2014-06-30 2.79 -9.25 6.81 4.02
2014-03-31 3.16 -8.17 6.90 3.13
2013-12-31 3.54 -7.10 7.00 2.24
2013-09-30 3.77 -7.31 7.93 2.43
2013-06-30 4.00 -7.53 8.86 2.62
2013-03-31 6.46 -4.95 8.55 2.62
2012-12-31 8.92 -2.38 8.23 2.61
2012-09-30 8.07 -2.64 7.86 2.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Newron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Newron Pharmaceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Newron Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Newron Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Newron Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NWRN Health

 How is Newron Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Newron Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Newron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Newron Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Newron Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Newron Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Newron Pharmaceuticals Company Filings, last reported 7 months ago.

SWX:NWRN Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 54.84 0.00 43.85
2018-09-30 54.84 0.00 43.85
2018-06-30 60.99 0.00 50.64
2018-03-31 60.99 0.00 50.64
2017-12-31 67.72 0.00 60.08
2017-09-30 67.72 0.00 60.08
2017-06-30 52.49 0.18 45.07
2017-03-31 52.49 0.18 45.07
2016-12-31 49.75 0.36 46.47
2016-09-30 49.75 0.36 46.47
2016-06-30 32.38 0.55 34.88
2016-03-31 32.38 0.55 34.88
2015-12-31 37.11 0.73 40.93
2015-09-30 37.11 0.73 40.93
2015-06-30 47.11 0.91 44.00
2015-03-31 47.11 0.91 44.00
2014-12-31 29.26 1.09 25.70
2014-09-30 29.26 1.09 25.70
2014-06-30 34.41 1.27 31.39
2014-03-31 34.41 1.27 31.39
2013-12-31 21.09 1.45 18.43
2013-09-30 21.09 1.45 18.43
2013-06-30 25.48 1.62 21.77
2013-03-31 25.48 1.62 21.77
2012-12-31 27.61 1.80 29.24
2012-09-30 27.61 1.80 29.24
  • Newron Pharmaceuticals has no debt.
  • Newron Pharmaceuticals has no debt compared to 5 years ago when it was 6.8%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Newron Pharmaceuticals has sufficient cash runway for 2.7 years based on current free cash flow.
  • Newron Pharmaceuticals has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of -3% each year.
X
Financial health checks
We assess Newron Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Newron Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NWRN Dividends

 What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Newron Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought CHF2,000 of Newron Pharmaceuticals shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Newron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Newron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:NWRN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 30 Stocks 3.1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 167 Stocks 3.1%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2.1%
Switzerland Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:NWRN Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Newron Pharmaceuticals has not reported any payouts.
  • Unable to verify if Newron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Newron Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Newron Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Newron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Newron Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Newron Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Newron Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NWRN Management

 What is the CEO of Newron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stefan Weber
COMPENSATION €647,000
AGE 54
TENURE AS CEO 7.2 years
CEO Bio

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 2012 and served as its Chief Financial Officer since May 2005 and served as its Member of Management Board. He served as Executive Vice President, Europe of Landis+Gyr AG since October 2004. He served as Chief Financial Officer of Aliga Pharmaceuticals AG and Biofrontera AG (Formerly, Biofrontera Pharmaceuticals GmbH) from 2001 to 2005. He served as the Chief Financial Officer of Girindus AG since 2000, where he was responsible for the execution of the IPO and Investor Relations. He served as Chief Executive Officer at VonRoll Isola and Group Vice President Biloit Corp. From 1987 to 1999, Mr. Weber worked at Lohmann GmbH & Co.KG. His final position at Lohmann GmbH & Co.KG, as head of the central finance and tax services from 1997 to 1999. He has built 19 years of industry experience in finance, including 3 years in senior management and six years as Chief Financial Officer of public and private biotech companies. He has been Executive Director of Newron Pharmaceuticals SpA since 2012. His track record includes a multitude of substantial financing transactions, being debt, equity and mezzanine as well as national and european grants. Mr. Weber holds Master's degree in Business Management from Fernuniversitaet Hagen (Diplom-Kaufmann).

CEO Compensation
  • Stefan's compensation has increased whilst company is loss making.
  • Stefan's remuneration is about average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Newron Pharmaceuticals management team in years:

7.2
Average Tenure
62
Average Age
  • The average tenure for the Newron Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Stefan Weber

TITLE
CEO & Executive Director
COMPENSATION
€647K
AGE
54
TENURE
7.2 yrs

Roberto Galli

TITLE
Vice President of Finance
TENURE
7.2 yrs

Marco Caremi

TITLE
Executive Vice President of Business Development
AGE
62
TENURE
7.2 yrs

Ravi Anand

TITLE
Chief Medical Officer
COMPENSATION
€1M
AGE
62
TENURE
14.3 yrs

Dennis Dionne

TITLE
Vice President of Commercial Affairs
AGE
69
TENURE
4.6 yrs
Board of Directors Tenure

Average tenure and age of the Newron Pharmaceuticals board of directors in years:

7
Average Tenure
62.5
Average Age
  • The tenure for the Newron Pharmaceuticals board of directors is about average.
Board of Directors

Ulrich Köstlin

TITLE
Non-Executive Chairman
COMPENSATION
€118K
AGE
67
TENURE
6.3 yrs

Stefan Weber

TITLE
CEO & Executive Director
COMPENSATION
€647K
AGE
54
TENURE
7.6 yrs

Richard Murphy

TITLE
Chairman of the Board of Statutory Auditors
COMPENSATION
€13K
AGE
55
TENURE
12.3 yrs

Patrick Langlois

TITLE
Non-Executive Director
COMPENSATION
€98K
AGE
74
TENURE
11.1 yrs

Don deBethizy

TITLE
Non-Executive Director
COMPENSATION
€95K
AGE
69
TENURE
5.4 yrs

Luca Benatti

TITLE
Non-Executive Director
COMPENSATION
€96K
AGE
58
TENURE
5.4 yrs

Ze’ Seltzer

TITLE
Member of Scientific & Clinical Advisory Board

Fabrizio Stocchi

TITLE
Member of Scientific and Clinical Advisory Board

Emilio Perucca

TITLE
Member of Scientific & Clinical Advisory Board

Paolo Marchettini

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Newron Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Newron Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NWRN News

Simply Wall St News

Does Market Volatility Impact Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Share Price?

See our latest analysis for Newron Pharmaceuticals What NWRN's beta value tells investors Given that it has a beta of 1.6, we can surmise that the Newron Pharmaceuticals share price has been fairly sensitive to market volatility (over the last 5 years). … Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies. … What this means for you: Beta only tells us that the Newron Pharmaceuticals share price is sensitive to broader market movements.

Simply Wall St -

When Will Newron Pharmaceuticals S.p.A. (VTX:NWRN) Turn A Profit?

I’ve put together a brief outline of industry analyst expectations for NWRN, its year of breakeven and its implied growth rate. … SWX:NWRN Past and Future Earnings, July 29th 2019 Underlying developments driving NWRN’s growth isn’t the focus of this broad overview, but, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. … For a more comprehensive look at NWRN, take a look at NWRN’s company page on Simply Wall St.

Simply Wall St -

What Kind Of Shareholders Own Newron Pharmaceuticals S.p.A. (VTX:NWRN)?

See our latest analysis for Newron Pharmaceuticals SWX:NWRN Ownership Summary, July 11th 2019 What Does The Institutional Ownership Tell Us About Newron Pharmaceuticals? … Insider Ownership Of Newron Pharmaceuticals The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Private Company Ownership We can see that Private Companies own 14%, of the shares on issue.

Simply Wall St -

Introducing Newron Pharmaceuticals (VTX:NWRN), The Stock That Slid 62% In The Last Five Years

See our latest analysis for Newron Pharmaceuticals Newron Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Over five years, Newron Pharmaceuticals grew its revenue at 27% per year. … You could get a better understanding of Newron Pharmaceuticals's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Simply Wall St -

How Newron Pharmaceuticals S.p.A. (VTX:NWRN) Could Add Value To Your Portfolio

In the case of NWRN, it is a company with strong financial health as well as a excellent growth outlook. … Flawless balance sheet with exceptional growth potential Investors in search for stocks with room to flourish should look no further than NWRN, with its expected earnings growth of 66%. … This implies that NWRN manages its cash and cost levels well, which is a crucial insight into the health of the company.

Simply Wall St -

One Thing To Remember About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Share Price

(VTX:NWRN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful.

Simply Wall St -

What Kind Of Investor Owns Most Of Newron Pharmaceuticals S.p.A. (VTX:NWRN)?

Generally speaking, as a company grows, institutions will increase their ownership. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Analysts Expect Breakeven For Newron Pharmaceuticals S.p.A. (VTX:NWRN)

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. … Many investors are wondering the rate at which NWRN will turn a profit, with the big question being “when will the company breakeven?” … In this article, I will touch on the expectations for NWRN’s growth and when analysts expect the company to become profitable

Simply Wall St -

Newron Pharmaceuticals S.p.A. (VTX:NWRN): Time For A Financial Health Check

However, the trade-off is NWRN will have to adhere to stricter debt covenants and have less financial flexibility. … Is NWRN right in choosing financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

What Kind Of Shareholders Own Newron Pharmaceuticals SpA (VTX:NWRN)?

The big shareholder groups in Newron Pharmaceuticals SpA (VTX:NWRN) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Newron Pharmaceuticals is not a large company by global standards.

Simply Wall St -

NWRN Company Info

Description

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson’s disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.

Details
Name: Newron Pharmaceuticals S.p.A.
NWRN
Exchange: SWX
Founded: 1998
CHF105,287,535
17,845,345
Website: http://www.newron.com
Address: Newron Pharmaceuticals S.p.A.
Via Ludovico Ariosto 21,
Bresso,
Milan, 20091,
Italy
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX NWRN Ordinary Shares SIX Swiss Exchange CH CHF 12. Dec 2006
OTCPK NWPH.F Ordinary Shares Pink Sheets LLC US USD 12. Dec 2006
DB NP5 Ordinary Shares Deutsche Boerse AG DE EUR 12. Dec 2006
XTRA NP5 Ordinary Shares XETRA Trading Platform DE EUR 12. Dec 2006
LSE 0QOI Ordinary Shares London Stock Exchange GB CHF 12. Dec 2006
Number of employees
Current staff
Staff numbers
24
Newron Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/16 20:57
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/08/03
Last earnings filing: 2019/03/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.